Topic:

R&D

Latest Headlines

Latest Headlines

MIT to launch nonprofit focused on empirical evaluation of digital health products

MIT's Hacking Medicine program, which studies digital health and medicine, is set to become a nonprofit institute devoted to empirically evaluating the real-world effectiveness of the latest medical gadgets, gizmos, smartphone apps and the like.  

Breakthrough anti-anticoagulants from Boehringer, Portola post stellar PhIII data

Portola Pharmaceuticals has laid out the last batch of Phase III data on its "breakthrough" anti-anticoagulant andexanet alfa, filling in the numbers that will be reviewed by regulators considering the biotech's upcoming pitch for marketing approval. And right alongside that announcement comes the latest numbers from Boehringer Ingelheim's breakthrough program for idarucizumab, which is already under review as an antidote to its blockbuster Pradaxa.

Medtronic reports early pivotal data for tiny leadless pacemaker with U.S. launch slated in a year or so

Cardiac Rhythm & Heart Failure is one of Medtronic's faster growing businesses, driven in part by the launch of tiny subcutaneous heart monitor Reveal Linq. The medical device giant expects that the launch of supersmall leadless pacemaker Micra Transcatheter Pacing System could help it to keep that revenue growth momentum going.

Amgen's Vectibix hits PhIII survival goal in previously treated mCRC patients

The treatment trumped best supportive care in patients who had failed to respond to chemo, posting a statistically significant improvement in overall survival to nail the primary endpoint of a Phase III study.

Bayer plans to dial up its R&D budget on the hunt for new blockbusters

Bayer is gearing up to spend more than ever before on R&D this year, CEO Marijn Dekkers said, investing in innovation with hopes of pushing some promising therapies onto the market.

PureTech banks $171M in a London IPO to fund its biotech bets

Biotech startup engine PureTech pulled off a $171 million IPO on the London Stock Exchange, crossing the Atlantic to raise cash for its hybrid approach to venture investing.

Lilly and Teva tout new migraine data amid a crowded race

Eli Lilly and Teva, racing with a pack of drugmakers with a new approach to treating migraines, said their respective injected therapies succeeded in midstage trials, setting the stage for pivotal studies.

Antibiotics biotech Nabriva shoots for a $92M IPO

Austrian drug developer Nabriva Therapeutics is plotting to make its way to Wall Street in a $92 million IPO, raising cash to support its pipeline of treatments for infectious diseases.

Video: Blazing a short path to an accelerated approval in oncology

At the 2015 BIO conference in Philadelphia, FierceBiotech Editor-in-Chief John Carroll moderates a discussion on the future of cancer R&D, featuring leaders from AstraZeneca, Juno Therapeutics, Merck, Johnson & Johnson and GlaxoSmithKline.

Medtronic buys into Arsenal, gets option to purchase the post-surgical foam startup subsidiary

Medtronic has invested in a subsidiary of Arsenal Medical, a startup focused on developing a polymer-based foam to control intra-abdominal bleeding. The device giant gains an option to acquire the subsidiary, Arsenal AAA, upon the achievement of undisclosed milestones. Medtronic also didn't reveal how much it invested in the deal.